Screener
ArriVent BioPharma, Inc. AVBP Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 348,700 | 332,897 |
| Right of use assets – operating leases | 370 | 13 |
| Deferred offering costs | 69 | 69 |
| Other assets | 156 | 190 |
| Total assets | $349,295 | $333,169 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,727 | $5,934 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets?
- ArriVent BioPharma, Inc. (AVBP) reported deferred tax assets and other non-current assets of $156K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets decreased by 11.4% year-over-year, from $176K to $156K.
- What is the long-term trend for ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets has grown at a 33.3% compound annual growth rate (CAGR), from $107K to $190K.
Ask your AI about ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude